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In this issue of Cell Stem Cell, Somervaille et al. (2009) have demonstrated convincingly that reversion to an
embryonic transcriptional program through defective MLL gene expression contributes to the generation of
myeloid leukemia stem cells.The mixed-lineage leukemia (MLL) tran-
scription factor gene is homologous to
the Drosophila trithorax (Trx) gene, which
is critical for interpreting homeotic signals
during embryonic patterning of the axial
skeleton (Emerling et al., 2002). Disruption
ofMLL expression at embryonic day 16.5
(E16.5) is lethal, in part because it
results in decreasedHox gene expression
and impaired embryonic hematopoiesis
(McMahon et al., 2007). Following the
expression of MLL in the region of the
dorsal aorta and developing gonads and
mesonephric kidney (AGM), definitive
hematopoiesis takes place, resulting in
seeding of the fetal liver (Ernst et al.,
2004). Conditional MLL deletion in adult
mouse models is characterized by the
production of hematopoietic stem cells
(HSCs) that are defective in self-renewal
and therefore are at a competitive disad-
vantage compared with wild-type HSCs
(McMahon et al., 2007; Jude et al.,
2007). Clearly, MLL expression exerts
distinct effects at different stages of
hematopoiesis. Although MLL maintains
quiescence of HSCs, it also promotes
proliferation of progenitors (Jude et al.,
2007). The protean nature of MLL makes
it particularly potent as an oncogene.
MLL is a critical regulator of normal
hematopoietic development during emb-
ryogenesis as well as in adult hematopoi-
esis. However, the precise role of MLL
and its translocation partners in altering
the transcriptional fate of MLL-driven
leukemias remained to be determined.
By employing global gene expression
profiling and targeted disruption or
overexpression of transcription factors
normally active in embryonic stem cells
(ESCs), Somervaille and colleagues
demonstrate that postnatal reversion toan embryonic transcriptional program
results in the generation andmaintenance
of myeloid leukemia stem cells (LSCs).
When MLL expression is disrupted in
myeloid progenitors, transcription/chro-
matin regulatory factors responsible for
maintaining self-renewal in HSCs, includ-
ing Hmgb3, Myb, and Cbx5, are coordi-
nately expressed, leading to aberrant
acquisition of self-renewal capacity. An
early hypothesis regarding the origin of
cancer suggested that malignancies
arose from postnatal persistence of
embryonic tissue. Although this hypoth-
esis has essentially been put to rest, this
paper posits that activation of an
MLL-mediated embryonic transcriptional
program in more mature myeloid progen-
itors contributes to acquisition of charac-
teristics normally ascribed to developing
HSCs. This hypothesis is supported
by the capacity of MLL-reprogrammed
myeloid leukemic progenitors to self-
renew as well as to undergo differentia-
tion, survive, and home to hematopoietic
niches.
Since LSCs were first identified in acute
myeloid leukemia (AML), much has been
learned about the phenotypic identity of
cancer stem cells in other hematologic
malignancies and solid tumors (reviewed
in Clarke et al., 2006). Related research
has demonstrated that LSCs in specific
mouse and human myeloid leukemias
retain some of the phenotypic and tran-
scriptional features of the committed
myeloidprogenitors fromwhich theyarose
(Krivtsov et al., 2006; Jamieson et al.,
2004). Moreover, deregulation of potent
oncogenes, including the MLL gene that
is expressed in more than half of infant
leukemias, contributes to initiation and/
or maintenance of the LSC population,Cell Stem Cedepending on the microenvironmental
context (Cozzio et al., 2003; Barabe´
et al., 2007). Another seminal report estab-
lished that deregulated MLL expression
could activate self-renewal programs in
myeloid progenitors, leading to LSC
generation (Krivtsov et al., 2006). The
current study by Somervaille et al. (2009)
extends these findings by making the
important link between activation of an
embryonic-like transcriptional program at
an inappropriate stage of development
and an increased frequency of self-renew-
ing progenitor-like LSCs leading to a poor
prognosis in leukemia. The authors made
this critical conclusion by investigating
the genetic drivers that maintain LSC at
the apex of the hierarchy of cells capable
of propagating leukemia in amousemodel
that recapitulates many features of
MLL-associated AML.
Importantly,Somervaille andcolleagues
discovered that LSC frequency varied
significantly depending on the MLL
translocation partner, which altered the
capacity of MLL to subvert self-renewal
programs. The most potent MLL fusion
genes included MLL-AF9 and MLL-ENL.
Expression of these MLL fusion genes
gives rise to a higher frequency of LSCs
and a more primitive leukemia phenotype
than MLL-AF10, MLL-GAS7, or MLL-
AF1p, indicating that a functional hierarchy
among MLL fusion genes leads to varying
LSC frequencies. In MLL leukemias typi-
fied by a high frequency of LSCs, the
LSCs shared key transcriptional features
with ESCs. These ESC programs, charac-
terized by increased expression of chro-
matin/transcriptional regulatory genes
including Orc21, Mtf2, Cbx5, and
Hmgb3, were subverted byMLL oncopro-
teins within myeloid progenitors, therebyll 4, February 6, 2009 ª2009 Elsevier Inc. 97
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Previewsmaintaining self-renewal and leading to
a poor prognosis. Notably, combined
expression of Myb, Cbx5, and Hmgb3
expression was reduced following condi-
tional inactivation of the MLL-ENL onco-
protein commensurate with loss of LSC
clonogenic activity and induction of differ-
entiation into macrophages. Similarly,
Myb knockdown decreased LSC fre-
quency and induced LSC differentiation.
However, coincident expression of all
three genes was required to induce the
serial replating capacity characteristic of
LSCs. Finally, although previous reports
indicated that LSCs may be quiescent,
this study demonstrates that the AML
bone marrow population containing the
highest frequency of cycling cells also
harbors the highest frequency of LSCs.
While this does not obviate the possibility
that some leukemias are generated by
primarily quiescent LSCs, MLL-driven
mouse myeloid leukemias appear to be
propagated bymetabolically active, prolif-
erating LSCs.Exploring Pluripot
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In a recent issue of Chemistry & Bio
the role of glycogen synthase kinas
and tools for modulating this proce
Themultifunctional serine-threoninekinase,
glycogen synthase kinase-3 (GSK-3),
has recently been identified as a critical
modulator of embryonic stem cell (ESC)
properties, largely based on experiments
using selective GSK-3 inhibitors. Due to
the use of various cell lines (from mouse
and human), inconsistency in cell culture
conditions, and experimental assays, as
well as different small molecule inhibitors
of GSK-3, the precise role that GSK-3 plays
in ESCs has been somewhat ambiguous.
Bone et al. used a macrocyclic bisindolyl-
98 Cell Stem Cell 4, February 6, 2009 ª2009By dissecting the molecular pathways
involved in LSC generation in response
to MLL deregulation, Somervaille and
colleagues have significantly advanced
the field of cancer stem cell research by
linking the extent of subversion of embry-
onic transcriptional programs involved in
regulating self-renewal and the frequency
of LSCs. They have provided important
insights into the genetic factors regulating
the frequency of LSCs as well as the most
critical pathways to target in clinical trials.
This seminal work is likely to have far-
reaching implications for the design of
novel therapies targeting cancer stem
cells in other malignancies.
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canonical Wnt activation in both mouse
and human ESCs promotes their differenti-
ation into multipotent mesendodermal
progenitors or their differentiated progeny
(Bakre et al., 2007; Dravid et al., 2005).
While most studies with GSK-3 inhibitors
and ESCs support a role for GSK-3 in the
maintenance of undifferentiated pluripotent
cells, the GSK-3 inhibitor TWS119 was
reported to induce neuronal differentiation
of ESCs (Ding et al., 2003).
The standardmethodused topropagate
mouse ESCs (mESCs) is in rich medium,
